Utilizing panels of patient derived xenografts to aid the development of antibody drug conjugates

Despite numerous endeavors in clinical trials there are few clinically approved Antibody Drug Conjugate (ADC) therapies. Here we comment on our recent publication demonstrating the power of using panels of patient-derived xenografts (PDX) prior to Phase 1, to assess the potential heterogeneity of re...

Descripción completa

Detalles Bibliográficos
Autores principales: Collins, Scott David, Bialucha, Carl Uli, Williams, Juliet Anne, Gao, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791866/
https://www.ncbi.nlm.nih.gov/pubmed/29404392
http://dx.doi.org/10.1080/23723556.2017.1394422
_version_ 1783296672287162368
author Collins, Scott David
Bialucha, Carl Uli
Williams, Juliet Anne
Gao, Hui
author_facet Collins, Scott David
Bialucha, Carl Uli
Williams, Juliet Anne
Gao, Hui
author_sort Collins, Scott David
collection PubMed
description Despite numerous endeavors in clinical trials there are few clinically approved Antibody Drug Conjugate (ADC) therapies. Here we comment on our recent publication demonstrating the power of using panels of patient-derived xenografts (PDX) prior to Phase 1, to assess the potential heterogeneity of response a clinical candidate may show across a population. Furthermore we discuss how the same approach has been used in an additional ADC program.
format Online
Article
Text
id pubmed-5791866
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-57918662018-11-30 Utilizing panels of patient derived xenografts to aid the development of antibody drug conjugates Collins, Scott David Bialucha, Carl Uli Williams, Juliet Anne Gao, Hui Mol Cell Oncol Commentary Despite numerous endeavors in clinical trials there are few clinically approved Antibody Drug Conjugate (ADC) therapies. Here we comment on our recent publication demonstrating the power of using panels of patient-derived xenografts (PDX) prior to Phase 1, to assess the potential heterogeneity of response a clinical candidate may show across a population. Furthermore we discuss how the same approach has been used in an additional ADC program. Taylor & Francis 2017-11-30 /pmc/articles/PMC5791866/ /pubmed/29404392 http://dx.doi.org/10.1080/23723556.2017.1394422 Text en © 2018 The Author(s). Published by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Commentary
Collins, Scott David
Bialucha, Carl Uli
Williams, Juliet Anne
Gao, Hui
Utilizing panels of patient derived xenografts to aid the development of antibody drug conjugates
title Utilizing panels of patient derived xenografts to aid the development of antibody drug conjugates
title_full Utilizing panels of patient derived xenografts to aid the development of antibody drug conjugates
title_fullStr Utilizing panels of patient derived xenografts to aid the development of antibody drug conjugates
title_full_unstemmed Utilizing panels of patient derived xenografts to aid the development of antibody drug conjugates
title_short Utilizing panels of patient derived xenografts to aid the development of antibody drug conjugates
title_sort utilizing panels of patient derived xenografts to aid the development of antibody drug conjugates
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791866/
https://www.ncbi.nlm.nih.gov/pubmed/29404392
http://dx.doi.org/10.1080/23723556.2017.1394422
work_keys_str_mv AT collinsscottdavid utilizingpanelsofpatientderivedxenograftstoaidthedevelopmentofantibodydrugconjugates
AT bialuchacarluli utilizingpanelsofpatientderivedxenograftstoaidthedevelopmentofantibodydrugconjugates
AT williamsjulietanne utilizingpanelsofpatientderivedxenograftstoaidthedevelopmentofantibodydrugconjugates
AT gaohui utilizingpanelsofpatientderivedxenograftstoaidthedevelopmentofantibodydrugconjugates

Ejemplares similares